Technology ID
TAB-4625
Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness-Associated Homeostatic Reset
E-Numbers
E-033-2019-0
Lead Inventor
Klimas, Nancy
Lead IC
CDC
Co-Inventors
O'Callaghan, James
Craddock, Travis
Morris, Mariana
Broderick, Gordon
Fletcher, Maryann
ICs
CDC
Applications
Therapeutics
Research Materials
Development Stages
Pre-Clinical (in vitro)
This technology includes therapeutics for Gulf War Illness (GWI). (GWI) patient symptoms, clinical laboratory tests and computational analyses of results from genomic, immunological, autonomic and endocrine changes in animal models therapeutic target were narrowed down to tumor necrosis factor (TNF) and Glucocorticoid receptor for a carefully timed “two hit” treatment model, manipulating cytokine mediated inflammation and the HPA axis.
Commercial Applications
Drugs targeting the TNF and Glucocorticoid receptors could be repurposed to use in treatment of multi symptom illnesses such as GWI and ME/CFS associated homeostatic reset.
Competitive Advantages
Genomic, immunological, autonomic and endocrine changes observed in GW veterans were assessed and used to discover the pathological pathways and key mediators underlying GWI, then identified therapeutic targets that manipulate those pathways.
Licensing Contact: